GlaxoSmithKline Teams with EMBL-EBI, Sanger Institute to Launch Target Validation Center | GenomeWeb

NEW YORK (GenomeWeb News) – In an effort to address the high failure rate of drug candidates in clinical studies, the Wellcome Trust Sanger Institute, the European Bioinformatics Institute, and GlaxoSmithKline have partnered to create a new center that will use genomics and big data technologies to validate drug targets, EMBL-EBI said today.

Based at the Wellcome Trust Genome Campus near Cambridge, the Centre for Therapeutic Target Validation (CTTV) will launch with a £1 million ($1.7 million) investment from GSK that will fuel its initial research projects.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.